Q3 2024 and Recent Highlights
NEW YORK, Nov. 7, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced its financial results for the third quarter of 2024, highlighting substantial improvements in financial performance and business momentum.
The Company delivered revenue growth and multiple key client wins, laying a solid foundation for 2025. These achievements not only demonstrate continued progress in financial metrics, but also reflect the successful execution of long-term strategic initiatives aimed at driving sustainable growth.
"Our third quarter included strong execution of our multi-year strategic plan of being a profitable provider of comprehensive chronic care management solutions which engage members and improve outcomes at a reduced cost of care," said Erez Raphael, CEO of Dario. "Our efforts to streamline costs following the Twill merger, combined with revenue growth across multiple channels, have positioned us for ongoing success. We're seeing clear progress in our transformation, and we remain focused on achieving profitability run rate by the end of 2025."
The Company reported improvement across all key financial metrics, both sequentially and year-over-year. Q3 revenue reached $7.42 million, an increase of 18.7% from Q2 2024 and a 111% increase compared to Q3 2023, driven primarily by growth in the Company's core Business-to-Business-to-Consumer (B2B2C) business.
Through continued optimization of revenue channels and a transition to recurring revenue models, gross margins for the B2B2C business rose to 83%, with full business gross margins reaching 52% and pro-forma gross margins reaching 70.3% (on a non-Generally Accepted Accounting Principles (GAAP) basis).
Following the recent acquisition of Twill, Dario implemented focused cost-management strategies, reducing GAAP operating expenses to $15.9 million, a 16% sequential reduction from Q2 2024 and non-GAAP operating expenses to $12.3 million, a 15.9% reduction from Q2 2024.
"We are not just growing; we believe that we are improving the quality and predictability of our revenues," said Steven Nelson, Chief Commercial Officer at Dario. "Securing 10 new clients this quarter, combined with diversifying our revenue streams, ensures that we are on a path for sustained success in 2025 and beyond."
The Company reported a 25.7% reduction in GAAP operating losses sequentially, lowering such losses to $12 million, and 33.3% reduction in non-GAAP operating losses, lowering such losses to $7.1 million.
Looking ahead, Dario expects this positive trend in financial performance to continue, driven by ongoing revenue growth, increasing gross margins due to positive mix shift and operating leverage related to our reduced fixed expenses. The Company anticipates a 38% reduction in total operating expenses between Q1 2024 and Q1 2025, alongside a 49% reduction in operating losses and a 59% reduction in non-GAAP operating losses respectively, paving the way to achieve cash flow breakeven run rate by the end of 2025.
Business Highlights
In Q3, the Company enhanced its commercial momentum by securing 10 new clients, positioning itself for strong growth in 2025. Dario focused on not only increasing revenues but also making them more sustainable by diversifying across channels and clients. This effort included transforming the pharma channel—previously the Company's only non-recurring revenue stream—into a recurring revenue model.
Additionally, this quarter marked the completion of the integration of Twill's capabilities into Dario's full multi-condition platform. The combined behavioral health, well-being, navigation, and engagement technologies now create the most comprehensive solution in the digital health market under the Dario brand.
"We are excited about the growing opportunities for our artificial intelligence (AI) capabilities, especially as data becomes an increasingly vital asset in our business model," Erez Raphael added. "By integrating generative AI and microservices, we believe we are poised to revolutionize areas like drug discovery, consumer engagement, and personalization, with our proprietary data setting us up for both internal and external monetization."
With its market-leading expertise, Dario is well-positioned to capitalize on these emerging trends and continue delivering value to its stakeholders.
Third Quarter 2024 Results Summary
Revenues for the third quarter ended September 30, 2024, were $7.42 million, an 111% increase from $3.52 million for the third quarter ended September 30, 2023, and an increase of 18.7% from $6.26 million for the second quarter of 2024. The increase compared to the quarter ended September 30, 2023, resulted from an increase in revenues from the B2B2C channel and the consolidation of Twill revenues.
B2B2C, employers and health plans recurring revenues for the third quarter ended September 30, 2024, were $5.44 million compared to $1.29 million in the quarter ended September 30, 2023, representing an increase of 320%, and compared to $5.54 million in the second quarter of 2024, representing a decrease of 1.9% sequentially.
Gross profit for the third quarter ended September 30, 2024, was $3.9 million, an increase of $3.3 million or 534%, compared to gross profit of $610,000 for the third quarter of 2023, and an increase of 41% from $2.76 million for the second quarter of 2024. The reason for this increase is the increase in our B2B2C revenues. Gross profit as a percentage of revenues increased to 52.2% in the third quarter of 2024, from 17.3% in the third quarter of 2023, and 44.1% in the second quarter of 2024.
Pro-forma gross profit, excluding $1.34 million of amortization expenses related to the acquisition of technology, was $5.2 million, or 70.3% of revenues, for the three months ended September 30, 2024, compared to pro-forma gross profit of $1.7 million, or 48.8% of revenues, for the three months ended September 30, 2023, and a pro-forma gross profit of $4.0 million, or 63.8% of revenues, for the three months ended June 30, 2024. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Total operating expenses for the third quarter ended September 30, 2024, were $15.9 million compared to $16.2 million for the third quarter ended September 30, 2023, and $18.9 million for the second quarter of 2024, a decrease of $0.25 million, or 1.5%, compared to the third quarter of 2023, and a decrease of $3 million, or 16%, compared to the second quarter of 2024. The decrease compared to the third quarter ended September 30, 2023, resulted mainly from reduction in operating expenses. The decrease compared to the second quarter of 2024 resulted mainly from a decrease in operating expenses and stock-based compensation expenses.
Total operating expenses excluding stock-based compensation, acquisition related expenses and depreciation for the third quarter of 2024 were $12.3 million compared to $10.9 million for the third quarter of 2023, and $14.7 million for the second quarter of 2024.
Operating loss for the third quarter of 2024 was $12 million, a decrease of $3.5 million, or 23%, compared to $15.5 million for the third quarter of 2023, and a decrease of $4.2 million, or 25.7%, compared to $16.2 million for the second quarter of 2024. The decrease compared to the third quarter of 2023 was due to the increase in the gross profit. The decrease compared to the second quarter of 2024 was mainly due to the decrease in operating expenses.
Financing expenses were $0.3 million for the third quarter of 2024, compared to financing expenses of $0.2 million for the third quarter of 2023. The reason for this increase was due to changes in variable items included in the financing expenses.
Net loss was $12.3 million in the third quarter of 2024, a decrease of $3.4 million, or 21.6%, compared to a net loss of $15.7 million in the third quarter of 2023, and a decrease of $1.3 million, or 9.4%, compared to $13.6 million in the second quarter of 2024.
Net loss excluding stock-based compensation, acquisition related expenses and depreciation for the third quarter of 2024 was $7.4 million compared to a loss of $9.3 million for the third quarter of 2023, and a net loss of $8.1 million in the second quarter of 2024.
A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Financial Results for the Nine Months Ended September 30, 2024:
Revenues for the nine months ended September 30, 2024, were $19.4 million, a 16.1% increase from $16.7 million for the nine months ended September 30, 2023.
Gross profit for the nine months ended September 30, 2024, was $9.1 million, an increase of 55%, or $3.2 million, compared to gross profit of $5.9 million for the nine months ended September 30, 2023.
Pro-forma gross profit, excluding $3.7 million of amortization of expenses related to acquisitions, was $12.8 million for the nine months ended September 30, 2024, compared to a pro-forma gross profit of $9.1 million for the nine months ended September 30, 2023. Pro-forma gross profit margin, excluding amortization of acquisition related expenses, was 65.9% for the nine months ended September 30, 2024, compared to 54.6% for the nine months ended September 30, 2023. A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Total operating expenses for the nine months ended September 30, 2024, were $55.1 million, an increase of $7.3 million, or 15.3%, compared with $47.8 million for the nine months ended September 30, 2023. The increase resulted from the acquisition of Twill. Total operating expenses excluding stock-based compensation, amortization of acquisition related expenses and depreciation for the nine months ended September 30, 2024, were $39.7 million compared to $32.3 million for the nine months ended September 30, 2023.
Operating loss for the nine months ended September 30, 2024, increased by $4.1 million to $46.1 million, compared to a $42 million operating loss for the nine months ended September 30, 2023. This increase is mainly due to the increase in operating expenses.
Financing income was $11 million for the nine months ended September 30, 2024, compared to financing expense of $3.2 million for the nine months ended September 30, 2023. The reason for this increase was the revaluation of the pre-funded warrants issued as part of the consideration for the acquisition of Twill, due to its classification as a liability according to GAAP rules.
Net loss was $33.1 million for the nine months ended September 30, 2024, compared to a net loss of $45.1 million for the nine months ended September 30, 2023. The decrease was driven by the increase in financing income.
Net loss excluding stock-based compensation, acquisition related expenses and depreciation for the nine months ended September 30, 2024, was $13.9 million compared to a loss of $26.2 million for the nine months ended September 30, 2023.
A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Conference Call Details: Thursday, November 7, 8:30am ET
Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)
Call me™: https://emportal.ink/3SOTLAn
Participants can use the dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to scheduled start time.
Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1685062&tp_key=51068b0c30
Participants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion through Thursday, November 21st, 2024. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 1131131.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Our user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of the Company related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, when the Company discusses its expected reduced operating expenses expected by Q1 2025 and the resulting operating losses by such time period, that it expects to reach breakeven by the end of 2025, its expected breakeven timeline is supported by its progress in its high margin B2B2C channel, that its reduction of costs following the acquisition of Twill, combined with revenue growth across multiple channels, positions the Company for ongoing success, that it believes it sees clear progress in its transformation and remains focused on achieving a profitably run rate by the end of 2025, that it expects the positive trends in financial performance to continue, driven by ongoing revenue growth, increasing gross margins due to positive mix shift and operating leverage related to its reduced fixed expenses, its expected reduction in total operating expenses between Q1 2024 and Q1 2025, its expected reduction in operating losses and in non-GAAP operating losses respectively, paving the way to achieve cash flow breakeven run rate by the end of 2025, that it is positioned for strong growth in 2025, its plan to transform its pharmaceutical channel into a recurring revenue model, that its belief that two new contracts with a pharmaceutical company and a medical device company will contribute to the Company's revenue in the near term, its belief that the combined behavioral health, well-being, navigation, and engagement technologies now create the most comprehensive solution in the digital health market under the Dario brand, its belief that, by integrating generative AI and microservices, the Company is poised to revolutionize areas like drug discovery, consumer engagement, and personalization, with our proprietary data setting us up for both internal and external monetization and its belief that with its market-leading expertise, Dario is well-positioned to capitalize on these emerging trends and continue delivering value to its stakeholders. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Non-GAAP Financial Measures
We have provided in this release financial information that has not been prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. We use these non-GAAP financial measures internally in analyzing our financial results and believe they are useful to investors, as a supplement to GAAP measures, in evaluating our ongoing operational performance. We believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial results with peer companies, many of which present similar non-GAAP financial measures to investors.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures provided in the financial statement tables below.
Operating expenses (non-GAAP). Our presentation of non-GAAP operating expenses excludes stock-based compensation expenses, amortization of acquisition related expenses and depreciation of fixed assets. Due to varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash operating expenses, we believe that providing non-GAAP financial measures that exclude non-cash expenses provides us with an important tool for financial and operational decision making and for evaluating our own core business operating results over different periods of time.
Net loss (non-GAAP). Our presentation of adjusted net loss excludes the effect of certain items that are non-GAAP financial measures. Adjusted net loss represents net loss determined under GAAP without regard to stock-based compensation expenses, deferred inventory, depreciation of fixed assets, earn-out remeasurement and acquisition related expenses and amortization. We believe these measures provide useful information to management and investors for analysis of our operating results.
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||
INTERIM CONSOLIDATED BALANCE SHEETS | ||||||
U.S. dollars in thousands | ||||||
September 30, | December 31, | |||||
2024 | 2023 | |||||
Unaudited | ||||||
ASSETS | ||||||
CURRENT ASSETS: | ||||||
Cash and cash equivalents | $ | 15,547 | $ | 36,797 | ||
Short-term restricted bank deposits | 863 | 292 | ||||
Trade receivables, net | 4,948 | 3,155 | ||||
Inventories | 4,742 | 5,062 | ||||
Other accounts receivable and prepaid expenses | 3,428 | 2,024 | ||||
Total current assets | 29,528 | 47,330 | ||||
NON-CURRENT ASSETS: | ||||||
Deposits | 6 | 6 | ||||
Operating lease right of use assets | 1,306 | 967 | ||||
Long-term assets | 108 | 143 | ||||
Property and equipment, net | 1,235 | 899 | ||||
Intangible assets, net | 20,343 | 5,404 | ||||
Goodwill | 57,427 | 41,640 | ||||
Total non-current assets | 80,425 | 49,059 | ||||
Total assets | $ | 109,953 | $ | 96,389 | ||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||
INTERIM CONSOLIDATED BALANCE SHEETS | ||||||
U.S. dollars in thousands (except stock and stock data) | ||||||
September 30, | December 31, | |||||
2024 | 2023 | |||||
Unaudited | ||||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
CURRENT LIABILITIES: | ||||||
Trade payables | $ | 2,655 | $ | 1,131 | ||
Deferred revenues | 1,118 | 997 | ||||
Operating lease liabilities | 596 | 111 | ||||
Other accounts payable and accrued expenses | 5,807 | 6,300 | ||||
Current maturity of long-term loan | 8,670 | 3,954 | ||||
Total current liabilities | 18,846 | 12,493 | ||||
NON-CURRENT LIABILITIES | ||||||
Operating lease liabilities | 1,033 | 885 | ||||
Long-term loan | 20,187 | 24,591 | ||||
Warrant liability | 11,327 | 240 | ||||
Other long-term liabilities | 49 | 36 | ||||
Total non-current liabilities | 32,596 | 25,752 | ||||
STOCKHOLDERS' EQUITY | ||||||
Common stock of $0.0001 par value - authorized: 160,000,000 shares; issued and | 3 | 3 | ||||
Preferred stock of $0.0001 par value - authorized: 5,000,000 shares; issued and | *) - | *) - | ||||
Additional paid-in capital | 436,590 | 407,502 | ||||
Accumulated deficit | (378,082) | (349,361) | ||||
Total stockholders' equity | 58,511 | 58,144 | ||||
Total liabilities and stockholders' equity | $ | 109,953 | $ | 96,389 | ||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||||||||
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS | ||||||||||||
U.S. dollars in thousands (except stock and stock data) | ||||||||||||
Three months ended | Nine months ended | |||||||||||
September 30, | September 30, | |||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||
Unaudited | Unaudited | |||||||||||
Revenues: | ||||||||||||
Services | $ | 5,604 | $ | 1,765 | $ | 14,424 | $ | 11,171 | ||||
Consumer hardware | 1,819 | 1,753 | 5,012 | 5,565 | ||||||||
Total revenues | 7,423 | 3,518 | 19,436 | 16,736 | ||||||||
Cost of revenues: | ||||||||||||
Services | 920 | 599 | 2,845 | 3,701 | ||||||||
Consumer hardware | 1,282 | 1,203 | 3,786 | 3,902 | ||||||||
Amortization of acquired intangible assets | 1,344 | 1,106 | 3,740 | 3,281 | ||||||||
Total cost of revenues | 3,546 | 2,908 | 10,371 | 10,884 | ||||||||
Gross profit | 3,877 | 610 | 9,065 | 5,852 | ||||||||
Operating expenses: | ||||||||||||
Research and development | $ | 5,446 | $ | 5,665 | $ | 18,898 | $ | 16,052 | ||||
Sales and marketing | 6,733 | 6,363 | 20,775 | 19,163 | ||||||||
General and administrative | 3,728 | 4,128 | 15,468 | 12,611 | ||||||||
Total operating expenses | 15,907 | 16,156 | 55,141 | 47,826 | ||||||||
Operating loss | 12,030 | 15,546 | 46,076 | 41,974 | ||||||||
Total financial expenses (income), net | 313 | 186 | (10,954) | 3,168 | ||||||||
Loss before taxes | 12,343 | 15,732 | 35,122 | 45,142 | ||||||||
Income Tax | 13 | — | 2,007 | — | ||||||||
Net loss | $ | 12,330 | $ | 15,732 | $ | 33,115 | $ | 45,142 | ||||
Other comprehensive loss: | ||||||||||||
Deemed dividend (contribution) | $ | 2,278 | $ | 1,172 | $ | (4,394) | $ | 2,863 | ||||
Net loss attributable to common shareholders | $ | 14,608 | $ | 16,904 | $ | 28,721 | $ | 48,005 | ||||
Net loss per share: | ||||||||||||
Basic and diluted loss per share of common stock | $ | 0.25 | $ | 0.49 | $ | 0.52 | $ | 1.52 | ||||
Weighted average number of common stock used in | 40,417,421 | 28,815,604 | 39,093,575 | 28,195,216 | ||||||||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||
U.S. dollars in thousands | ||||||
Nine months ended | ||||||
September 30, | ||||||
2024 | 2023 | |||||
Unaudited | ||||||
Cash flows from operating activities: | ||||||
Net loss | $ | (33,115) | $ | (45,142) | ||
Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||
Stock-based compensation | 13,206 | 15,307 | ||||
Depreciation and impairment | 773 | 290 | ||||
Disposal of property and equipment | 7 | — | ||||
Change in operating lease right of use assets | 666 | 228 | ||||
Amortization of acquired intangible assets | 4,519 | 3,375 | ||||
Decrease in trade receivables, net | 1,536 | 1,883 | ||||
Increase in other accounts receivable, prepaid expense and long-term assets | (894) | (324) | ||||
Decrease in inventories | 320 | 2,485 | ||||
Decrease in trade payables | (886) | (393) | ||||
Decrease in other accounts payable and accrued expenses | (3,704) | (1,182) | ||||
Decrease in deferred revenues | (621) | (636) | ||||
Change in operating lease liabilities | (791) | (196) | ||||
Change in fair value of warrant liability | (13,370) | — | ||||
Non-Cash financial expenses | 432 | 1,267 | ||||
Other | 92 | — | ||||
Net cash used in operating activities | (31,830) | (23,038) | ||||
Cash flows from investing activities: | ||||||
Purchase of property and equipment | (117) | (501) | ||||
Purchase of short-term investments | — | (4,996) | ||||
Proceeds from redemption of short-term investments | — | 5,033 | ||||
Payments for business acquisitions, net of cash acquired | (8,796) | — | ||||
Net cash used in investing activities | (8,913) | (464) | ||||
Cash flows from financing activities: | ||||||
Proceeds from issuance of common stock, net of issuance costs | — | 1,614 | ||||
Proceeds from issuance of preferred stock, net of issuance costs | 20,206 | 14,868 | ||||
Proceeds from borrowings on credit agreement | — | 29,604 | ||||
Repayment of long-term loan | — | (27,833) | ||||
Net cash provided by financing activities | 20,206 | 18,253 | ||||
Decrease in cash, cash equivalents and restricted cash and cash equivalents | (20,537) | (5,249) | ||||
Effect of exchange rate differences on cash, cash equivalents and restricted cash and cash | (50) | — | ||||
Cash, cash equivalents and restricted cash and cash equivalents at beginning of period | 36,797 | 49,470 | ||||
Cash, cash equivalents and restricted cash and cash equivalents at end of period | $ | 16,210 | $ | 44,221 | ||
Supplemental disclosure of cash flow information: | ||||||
Cash paid during the period for interest on long-term loan | $ | 2,968 | $ | 3,035 | ||
Non-cash activities: | ||||||
Right-of-use assets obtained in exchange for lease liabilities | $ | 428 | $ | 14 | ||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
U.S. dollars in thousands | ||||||||
Three months ended September 30, 2024 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 3,546 | 7 | (1,359) | 2,194 | |||
Gross Profit | 3,877 | (7) | 1,359 | 5,229 | ||||
Research and development | 5,446 | (748) | (63) | 4,635 | ||||
Sales and Marketing | 6,733 | (948) | (689) | 5,096 | ||||
General and Administrative | 3,728 | (1,097) | (17) | 2,614 | ||||
Total Operating Expenses | 15,907 | (2,793) | (769) | 12,345 | ||||
Operating Loss | $ | (12,030) | 2,786 | 2,128 | (7,116) | |||
Financing expenses | 313 | - | - | 313 | ||||
Income Tax | (13) | (13) | ||||||
Net Loss | $ | (12,330) | 2,786 | 2,128 | (7,416) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
U.S. dollars in thousands | ||||||||
Three months ended September 30, 2023 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 2,908 | (17) | (1,137) | 1,754 | |||
Gross Profit | 610 | 17 | 1,137 | 1,764 | ||||
Research and development | 5,665 | (1,226) | (22) | 4,417 | ||||
Sales and Marketing | 6,363 | (1,879) | (39) | 4,445 | ||||
General and Administrative | 4,128 | (2,037) | (38) | 2,053 | ||||
Total Operating Expenses | 16,156 | (5,142) | (99) | 10,915 | ||||
Operating Loss | $ | (15,546) | 5,159 | 1,236 | (9,151) | |||
Financing expenses | 186 | - | 186 | |||||
Income Tax | - | - | ||||||
Net Loss | $ | (15,732) | 5,159 | 1,236 | (9,337) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
U.S. dollars in thousands | ||||||||
Nine months ended September 30, 2024 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 10,371 | (5) | (3,784) | 6,582 | |||
Gross Profit | 9,065 | 5 | 3,784 | 12,854 | ||||
Research and development | 18,898 | (2,311) | (187) | 16,400 | ||||
Sales and Marketing | 20,775 | (4,354) | (859) | 15,562 | ||||
General and Administrative | 15,468 | (6,536) | (1,175) | 7,757 | ||||
Total Operating Expenses | 55,141 | (13,201) | (2,221) | 39,719 | ||||
Operating Loss | $ | (46,076) | 13,206 | 6,005 | (26,865) | |||
Financing expenses | (10,954) | - | - | (10,954) | ||||
Income Tax | (2,007) | (2,007) | ||||||
Net Loss | $ | (33,115) | 13,206 | 6,005 | (13,904) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
U.S. dollars in thousands | ||||||||
Nine months ended September 30, 2023 | ||||||||
GAAP | Stock-Based | Amortization | Non-GAAP | |||||
Cost of Revenues | $ | 10,884 | (61) | (3,372) | 7,451 | |||
Gross Profit | 5,852 | 61 | 3,372 | 9,285 | ||||
Research and development | 16,052 | (3,713) | (57) | 12,282 | ||||
Sales and Marketing | 19,163 | (5,550) | (129) | 13,484 | ||||
General and Administrative | 12,611 | (5,983) | (107) | 6,521 | ||||
Total Operating Expenses | 47,826 | (15,246) | (293) | 32,287 | ||||
Operating Loss | $ | (41,974) | 15,307 | 3,665 | (23,002) | |||
Financing expenses | 3,168 | - | - | 3,168 | ||||
Income Tax | - | - | ||||||
Net Loss | $ | (45,142) | 15,307 | 3,665 | (26,170) | |||
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
This email address is being protected from spambots. You need JavaScript enabled to view it.
+315-378-6922
Media Contact:
Scott Stachowiak
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1-646-942-5630
| Last Trade: | US$0.66 |
| Daily Change: | -0.05 -7.68 |
| Daily Volume: | 164,032 |
| Market Cap: | US$22.510M |
November 04, 2024 October 17, 2024 October 01, 2024 September 12, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
